Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
School of PhD Studies, Semmelweis University, Budapest, Hungary.
PLoS One. 2022 Nov 16;17(11):e0277785. doi: 10.1371/journal.pone.0277785. eCollection 2022.
In many of the risk estimation algorithms for patients with ST-elevation myocardial infarction (STEMI), heart rate and systolic blood pressure are key predictors. Yet, these parameters may also be altered by the applied medical treatment / circulatory support without concomitant improvement in microcirculation. Therefore, we aimed to investigate whether venous lactate level, a well-known marker of microcirculatory failure, may have an added prognostic value on top of the conventional variables of the "Global Registry of Acute Coronary Events" (GRACE) 2.0 model for predicting 30-day all-cause mortality of STEMI patients treated with primary percutaneous coronary intervention (PCI).
In a prospective single-center registry study conducted from May 2020 through April 2021, we analyzed data of 323 cases. Venous blood gas analysis was performed in all patients at admission. Nested logistic regression models were built using the GRACE 2.0 score alone (base model) and with the addition of venous lactate level (expanded model) with 30-day all-cause mortality as primary outcome measure. Difference in model performance was analyzed by the likelihood ratio (LR) test and the integrated discrimination improvement (IDI). Independence of the predictors was evaluated by the variance inflation factor (VIF). Discrimination and calibration was characterized by the c-statistic and calibration intercept / slope, respectively.
Addition of lactate level to the GRACE 2.0 score improved the predictions of 30-day mortality significantly as assessed by both LR test (LR Chi-square = 8.7967, p = 0.0030) and IDI (IDI = 0.0685, p = 0.0402), suggesting that the expanded model may have better predictive ability than the GRACE 2.0 score. Furthermore, the VIF was 1.1203, indicating that the measured lactate values were independent of the calculated GRACE 2.0 scores.
Our results suggest that admission venous lactate level and the GRACE 2.0 score may be independent and additive predictors of 30-day all-cause mortality of STEMI patients treated with primary PCI.
在许多用于 ST 段抬高型心肌梗死(STEMI)患者的风险评估算法中,心率和收缩压是关键预测因素。然而,这些参数也可能因应用的医疗治疗/循环支持而改变,而微循环没有同时改善。因此,我们旨在研究静脉乳酸水平(一种已知的微循环衰竭标志物)是否在预测接受直接经皮冠状动脉介入治疗(PCI)的 STEMI 患者 30 天全因死亡率方面,除了“全球急性冠状动脉事件登记”(GRACE)2.0 模型的常规变量之外,是否具有额外的预后价值。
在一项从 2020 年 5 月至 2021 年 4 月进行的前瞻性单中心登记研究中,我们分析了 323 例患者的数据。所有患者入院时均进行静脉血气分析。使用 GRACE 2.0 评分(基础模型)和静脉乳酸水平(扩展模型)构建嵌套逻辑回归模型,以 30 天全因死亡率为主要结局指标。通过似然比(LR)检验和综合判别改善(IDI)分析模型性能的差异。通过方差膨胀因子(VIF)评估预测因子的独立性。通过 c 统计量和校准截距/斜率分别描述区分度和校准度。
将乳酸水平添加到 GRACE 2.0 评分中,通过 LR 检验(LR Chi-square = 8.7967,p = 0.0030)和 IDI(IDI = 0.0685,p = 0.0402)显著改善了 30 天死亡率的预测,这表明扩展模型可能比 GRACE 2.0 评分具有更好的预测能力。此外,VIF 为 1.1203,表明测量的乳酸值与计算的 GRACE 2.0 评分独立。
我们的结果表明,入院时的静脉乳酸水平和 GRACE 2.0 评分可能是接受直接 PCI 治疗的 STEMI 患者 30 天全因死亡率的独立且可相加的预测因素。